Category: Patent Profiles

    By Kwame Mensah — Digilab Peptidomics announced last month that the U.S. Patent and Trademark Office had granted U.S. Patent No. 7,202,044, which is directed to a panel of biomarkers for the diagnosis of chronic dementia or a predisposition to such diseases.  According to the company’s press release, by using proprietary Peptidomics® technologies,…

    By Christopher P. Singer — In an August 1, 2007 press release, Alnylam Pharmaceuticals, Inc. announced that the European Patent Office has issued a Rule 51(4) notification for European Patent 1 407 044 ("Tuschl II") which relates to RNA interference (RNAi) technology.  In the same release, Alnylam also stated that the corresponding application…

    By Baltazar Gomez — On June 26, 2007, Denmark-based 7TM Pharma A/S announced the grant of United Kingdom patents covering the use of the Obinepitide and TM30339 for treating obesity.  In 7TM Pharma’s statement, CEO Mette Kirstine Agger said the patents demonstrate the strength of 7TM Pharma’s patent position in the obesity area…

    By Christopher P. Singer — In a July 2, 2007 press release, Introgen Therapeutics, Inc. announced that the U.S. Patent Office has issued U.S. Patent No. 7,235,391, entitled "Formulations of Adenovirus for Gene Therapy."  The general technology covered by the patent relates to pharmaceutical formulations containing adenoviruses that have improved shipping and long…

    By Baltazar Gomez — On June 14, 2007, CryoLife, Inc. of Kennesaw, Georgia announced the grant of U.S. Patent No. 7,226,615 directed to BioFoam®, a protein hydrogel foam for rapidly filling and sealing open wounds.  CyroLife’s BioFoam® can be used in sports medicine for rapidly closing open wounds and allowing athletes to continue…

    By Donald Zuhn — Merrimack Pharmaceuticals, Inc. announced today (June 12, 2007) that it had been granted U.S. Patent No. 7,208,576.  The ‘576 patent, which relates to non-glycosylated human alpha-fetoprotein (huAFP) and biologically-active fragments of non-glycosylated huAFP, is the third U.S. patent to be awarded to the Cambridge, Massachusetts-based biotech company. According to…

Viral Mercenaries to The Rescue     By Baltazar Gomez — On May 29, 2007, Oncolytics Biotech Inc. of Calgary, Canada announced the grant of U.S. Patent No. 7,223,585, the biotech company’s twenty-first U.S. patent.  The ‘585 patent, entitled "Viral Purification Methods," covers the production and purification of viruses, specifically human reovirus (Respiratory Enteric Orphan…

    By Donald Zuhn — Last month, Koronis Pharmaceuticals, Inc. announced that the United States Patent and Trademark Office had issued a Notice of Allowance for its application directed to Koronis’ lead HIV therapeutic candidate, KP-1461.  The patent that eventually issues from the allowed application will be the first U.S. patent to be awarded…

    By Christopher P. Singer — Rosetta Genomics, Ltd. announced that U.S. Patent No. 7,217,807, entitled "Bioinformatically detectable group of novel HIV regulatory genes and uses thereof" has been granted by the U.S. Patent and Trademark Office.  The ‘807 patent relates to a group of viral RNA regulatory genes, termed "viral genomic address messenger…

    By Donald Zuhn — On Thursday, CEL-SCI Corporation announced that it had been granted U.S. Patent No. 7,199,216 by the U.S. Patent & Trademark Office.  The ‘216 patent relates to conjugated peptides in which an antigenic peptide that is associated with an immune disorder is covalently bonded to a T-cell binding ligand that…